Medlatest’s Review Of Week 29, 2012

It’s been a week in which companies have started issuing their results for Q2 and comparing them with the equivalent period a year ago. While it’s hard to summarise on behalf of the entire medtech industry, it looks like most big companies are keeping their heads out of the water.

Read about that and the week’s new products and approvals in View From The Med, Medlatest’s Friday trawl through the stories that have hit the headlines this week, here.